Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome (Nasdaq: IMNM) announced that on May 1, 2026 its Compensation Committee granted inducement non‑statutory stock options to purchase an aggregate of 450,000 shares to nineteen new employees under the 2024 Inducement Plan.
The options have an exercise price of $22.73 per share (closing price on May 1, 2026) and vest over four years: 25% at the one‑year anniversary and the remainder monthly over 36 months, subject to continued service and plan/agreement terms.
Immunome (Nasdaq: IMNM) submitted a New Drug Application to the U.S. FDA for varegacestat to treat adults with desmoid tumors, supported by positive Phase 3 RINGSIDE results.
The trial met its primary endpoint: progression-free survival improved with hazard ratio 0.16 (84% risk reduction; p<0.0001). Confirmed ORR was 56% vs 9% for placebo; most adverse events were grade 1–2.
Immunome (Nasdaq: IMNM) announced that Phase 3 RINGSIDE trial data for varegacestat in progressing desmoid tumors will be presented orally at the 2026 ASCO Annual Meeting in Chicago, May 29–June 2, 2026.
The oral abstract session is scheduled for May 30, 2026, 3:00 PM–6:00 PM CDT, with Mrinal M. Gounder, M.D. as presenter and Abstract 11506. According to the company, the presentation will build on positive topline data reported in December 2025.
Immunome (Nasdaq: IMNM) announced that on April 1, 2026 its Compensation Committee granted inducement non-statutory stock options totaling 188,500 shares to 13 new employees under the 2024 Inducement Plan.
The options carry an exercise price of $22.45 (closing price on April 1, 2026) and vest over four years (25% after one year, then monthly over 36 months), subject to continued service and the plan and option agreement terms.
Immunome (Nasdaq: IMNM) announced that on March 2, 2026 its Compensation Committee granted inducement awards of non-statutory stock options to seven new employees totaling 282,000 shares under the company’s 2024 Inducement Plan in reliance on Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price of $22.21 (closing price on March 2, 2026) and vests over four years: 25% at the one-year anniversary, then monthly over 36 months, subject to continued service and plan/option-agreement terms.
Immunome (Nasdaq: IMNM) reported full-year 2025 results and a business update. Key clinical and financial highlights include a planned NDA submission for varegacestat in 2Q 2026 after positive Phase 3 RINGSIDE results (PFS hazard ratio 0.16; ORR 56% vs 9%).
Pipeline and corporate items: IM-1021 Phase 1 ongoing with initial 2026 data, three ADC INDs planned in 2026, gross proceeds of $460.5M from a Dec 2025 offering, cash of $653.5M funding operations into 2028, and a 2025 net loss of $212.4M.
Immunome (Nasdaq: IMNM) said management will present at two investor conferences in March 2026: TD Cowen on March 3, 2026 at 9:50 a.m. ET and Leerink Partners on March 10, 2026 at 3:00 p.m. ET.
According to Immunome, live audio webcasts will be available via the company’s Investor Relations website and replays will remain accessible for approximately 30 days after each presentation.
Immunome (Nasdaq: IMNM) disclosed that on February 2, 2026 its Compensation Committee granted inducement non-statutory stock options for an aggregate of 30,000 shares to one new employee under the 2024 Inducement Plan.
The options have an exercise price of $26.14, equal to the February 2, 2026 closing price, and vest over four years with standard 25% one-year cliff and monthly vesting thereafter.
Immunome (NASDAQ: IMNM) will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026 at 9:00 a.m. ET.
Investors can access a live audio webcast via the company Investor Relations website at www.immunome.com; a replay will be available for approximately 30 days after the presentation.
Immunome (Nasdaq: IMNM) announced that on January 2, 2026 its Compensation Committee granted inducement non‑statutory stock options covering an aggregate of 93,000 shares to three new employees under the company’s 2024 Inducement Plan.
The options have an exercise price of $20.82 per share (the closing price on January 2, 2026) and vest over four years with 25% vesting at the one‑year anniversary and the remainder vesting monthly over the following 36 months, subject to continued service. Grants are subject to the 2024 Inducement Plan and individual option agreements.